Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors
Primary Purpose
Prostate Cancer
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Diabetes Prevention Program
Sponsored by
About this trial
This is an interventional prevention trial for Prostate Cancer focused on measuring insulin sensitivity, Diabetes Prevention Program, lifestyle intervention
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed prostate cancer
- Current Hormone therapy with GnRH agonist of 3 months or longer
- Overweight or obese (body mass index of 25kg/m2 or greater)
- No other conditions that prevent intensive lifestyle intervention
Exclusion Criteria:
- History of diabetes mellitus requiring drug therapy
- Hemoglobin Aic of 7% or greater
- Symptomatic metastatic disease
- Myocardial infarction within 6 months
- Treatment with anabolic agents or metabolic agents known to affect insulin or glucose levels
- Disease progression according to PSA Working Group Criteria
Sites / Locations
- Massachusetts General Hospital
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
A
B
Arm Description
Intensive lifestyle intervention based on the Diabetes Prevention Program
Will follow the guidelines for healthy living established by the Food Guide Pyramid and the National Cholesterol Education Program
Outcomes
Primary Outcome Measures
To evaluate the effect of intensive lifestyle modification on insulin sensitivity in men receiving GnRH agonist therapy for prostate cancer.
Secondary Outcome Measures
To evaluate the effects of intensive lifestyle modification on other markers of cardiovascular disease risk.
Full Information
NCT ID
NCT00738140
First Posted
June 23, 2008
Last Updated
July 9, 2013
Sponsor
Massachusetts General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00738140
Brief Title
Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors
Official Title
Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors
Study Type
Interventional
2. Study Status
Record Verification Date
July 2013
Overall Recruitment Status
Completed
Study Start Date
September 2007 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
September 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to discover if intensive lifestyle changes (such as diet and increased physical activity) improve the body's sensitivity to insulin, and therefore help prevent diabetes and other cardiovascular disease, in men receiving GnRH hormone therapy for prostate cancer.
Detailed Description
In this study, participants will be divided into two groups. One group will undergo intensive lifestyle changes (Lifestyle Intervention Group) designed by the Diabetes Prevention Group, and the other (Control Group) will follow the guidelines for healthy living established by the Food Guide Pyramid and the National Cholesterol Education Program.
All visits will take place at the General Clinical Research Center at the Massachusetts General Hospital.
At the initial visit, the following will be performed: Bionutrition evaluation; Oral Glucose Tolerance Test (OGTT); additional blood work and; Dual Energy X-Ray Absorptiometry (DXA) Scan.
After the initial visit, visits will be scheduled at 3, 6 and 12 months after and the above procedures will be repeated.
Participants will be randomized into one of the two study groups. Lifestyle Intervention Group: The goal for participants assigned to this group are to achieve and maintain a weight loss of at least 7% of initial body weight through a healthy low calorie, low fat diet and to engage in physical activity of moderate intensity. Control Group: participants in this group will receive standard nutrition and exercise recommendations from the Food Guide Pyramid and the National Cholesterol Education Program Step 1 diet to reduce body weight and increase physical activity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
Keywords
insulin sensitivity, Diabetes Prevention Program, lifestyle intervention
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Experimental
Arm Description
Intensive lifestyle intervention based on the Diabetes Prevention Program
Arm Title
B
Arm Type
No Intervention
Arm Description
Will follow the guidelines for healthy living established by the Food Guide Pyramid and the National Cholesterol Education Program
Intervention Type
Behavioral
Intervention Name(s)
Diabetes Prevention Program
Intervention Description
12-lesson program which will cover diet, exercise, and behavior modification.
Primary Outcome Measure Information:
Title
To evaluate the effect of intensive lifestyle modification on insulin sensitivity in men receiving GnRH agonist therapy for prostate cancer.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
To evaluate the effects of intensive lifestyle modification on other markers of cardiovascular disease risk.
Time Frame
1 year
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed prostate cancer
Current Hormone therapy with GnRH agonist of 3 months or longer
Overweight or obese (body mass index of 25kg/m2 or greater)
No other conditions that prevent intensive lifestyle intervention
Exclusion Criteria:
History of diabetes mellitus requiring drug therapy
Hemoglobin Aic of 7% or greater
Symptomatic metastatic disease
Myocardial infarction within 6 months
Treatment with anabolic agents or metabolic agents known to affect insulin or glucose levels
Disease progression according to PSA Working Group Criteria
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthew Smith, MD, PhD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors
We'll reach out to this number within 24 hrs